Serial 98412294
Live / Allowed — Third extension granted (statement of use) (as of 01 Jun 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 20 Feb 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98412294
- Mark type
- Design / logo
- Filed
- 20 Feb 2024
- Published for opposition
- 29 Oct 2024
- Attorney of record
- Peter Kunin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals, namely, small molecule therapeutic preparations for the correction of RNA expression, used in the treatment of cancers, cardiovascular diseases, immunological diseases, autoimmune diseases, neuromuscular diseases, blood disorders, rare genetic disorders, fibrosis; pharmaceuticals used in the treatment of cancers, cardiovascular diseases, immunological diseases, autoimmune diseases, neuromuscular diseases, blood disorders, rare genetic disorders, fibrosis
Owner
- Skyhawk Therapeutics, Inc., Waltham, MA, US
- Skyhawk Therapeutics, Inc., Waltham, MA, US
Prior registrations
Prosecution history
- 02 Jun 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Jun 2026 — SOU EXTENSION 3 GRANTED
- 01 Jun 2026 — SOU EXTENSION 3 FILED
- 01 Jun 2026 — SOU TEAS EXTENSION RECEIVED
- 03 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Dec 2025 — SOU EXTENSION 2 GRANTED
- 02 Dec 2025 — SOU EXTENSION 2 FILED
- 02 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 23 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 May 2025 — SOU EXTENSION 1 GRANTED
- 23 May 2025 — SOU EXTENSION 1 FILED
- 23 May 2025 — SOU TEAS EXTENSION RECEIVED
- 10 Dec 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 29 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Oct 2024 — PUBLISHED FOR OPPOSITION